Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 862,802 shares of the biopharmaceutical company’s stock after buying an additional 4,823 shares during the quarter. Geode Capital Management LLC’s holdings in Theravance Biopharma were worth $8,121,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in TBPH. Jane Street Group LLC grew its position in shares of Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 1,640 shares during the last quarter. Barclays PLC grew its position in Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after purchasing an additional 48,316 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Theravance Biopharma by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after purchasing an additional 7,620 shares during the period. SG Americas Securities LLC raised its holdings in shares of Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,349 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company’s stock worth $2,766,000 after buying an additional 2,060 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 370,038 shares of the company’s stock, valued at $3,330,342. The trade was a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Trading Up 1.0 %

TBPH stock opened at $9.54 on Friday. The firm’s 50-day moving average is $9.09 and its two-hundred day moving average is $9.18. The company has a market capitalization of $477.01 million, a price-to-earnings ratio of -9.45 and a beta of 0.14. Theravance Biopharma, Inc. has a 52 week low of $7.44 and a 52 week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The firm had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. On average, equities research analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.33.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.